The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Digital health company 1st Group (1ST) has received commitments to raise $4.5 million through a placement
  • The funds will be used to support 1st Group’s growth strategy including additional sales and marketing capabilities and technology development
  • The placement shares will be issued on or around December 18.
  • 1st group is up 5.48 per cent following news of the placement and shares are trading for 7.7 cents each

Digital health company 1st Group (1ST) has received commitments from institutional, sophisticated and professional investors for a $4.5 million placement.

The placement will issue 69,230,769 fully paid ordinary shares at an issue price of $0.065 per share; an 11 per cent discount to the last price before the trading halt.

Funds raised under the placement will be used to support 1st Group’s growth strategy including additional sales and marketing capabilities, technology development, working capital requirement and other general corporate purposes.

“We are delighted with the strong support shown by existing and new investors for 1st Group. This raise was initiated by institutional investor interest and reflects the confidence in our growth strategy and market opportunities,” CEO Klaus Bartosch said.

1st Group is a digital health company with integrated platforms that provide an easy way for health professionals and patients to book and schedule appointments.

The placement shares will be issued on or around December 18.

1st group is up 5.48 per cent following news of the placement and shares are trading for 7.7 cents each at 1:44 pm AEDT.

1ST by the numbers
More From The Market Online
Image of a woman holding a bottle of hemp oil

Little Green Pharma jumps into distribution with acquisition

Little Green Pharma is aiming to make the strategic acquisition of HH (Australia) Pty Ltd to…
Image of cancer cells

Radiopharm approved to start Lu-RAD202 safety trials, door open for in-human studies

Radiopharm Theranostics has received ethics approval for its trial into Lu-RAD202, a novel treatment for these…
Close up of a nasal spray

LTR Pharma pairs with Men’s Health Downunder for supply of erectile dysfunction spray

LTR Pharma Ltd has signed an agreement with Men's Health Downunder to facilitate supply of its…
Immune system concept ai gen

Immutep dips as safety test for flagship drug IMP761 shows no adverse effects

Immutep has reported a small-scale conceptual safety test among 5 patients using flagship drug IMP761 has…